Epigenomics teams up with Qiagen for colorectal cancer blood testing
This article was originally published in Clinica
Executive Summary
Qiagen could soon become the latest firm to market a colorectal cancer blood test based on Epigenomics' mSEPT9 biomarker. The former has licensed from Berlin, Germany-headquartered Epigenomics an option to commercialise, on a non-exclusive worldwide basis, a test based on the biomarker. The option can be exercised within two years.